Point72 Asia Singapore Pte. Ltd. Buys New Holdings in Eyenovia, Inc. (NASDAQ:EYEN)

Point72 Asia Singapore Pte. Ltd. purchased a new position in Eyenovia, Inc. (NASDAQ:EYEN) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 43,784 shares of the company’s stock, valued at approximately $26,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Armistice Capital LLC raised its position in shares of Eyenovia by 41.8% during the fourth quarter. Armistice Capital LLC now owns 4,378,000 shares of the company’s stock worth $9,106,000 after purchasing an additional 1,290,979 shares during the period. Vanguard Group Inc. increased its stake in Eyenovia by 25.2% during the 1st quarter. Vanguard Group Inc. now owns 1,790,501 shares of the company’s stock valued at $1,765,000 after purchasing an additional 360,924 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in Eyenovia by 1,444.4% during the first quarter. BNP Paribas Financial Markets now owns 219,610 shares of the company’s stock worth $217,000 after buying an additional 205,390 shares during the last quarter. Nations Financial Group Inc. IA ADV lifted its stake in shares of Eyenovia by 24.4% in the second quarter. Nations Financial Group Inc. IA ADV now owns 50,900 shares of the company’s stock valued at $30,000 after buying an additional 10,000 shares in the last quarter. Finally, Ground Swell Capital LLC acquired a new position in shares of Eyenovia during the second quarter valued at about $27,000. Institutional investors own 25.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Eyenovia in a research report on Tuesday, August 13th. William Blair upgraded Eyenovia to a “strong-buy” rating in a report on Friday, August 30th.

Eyenovia Stock Down 2.3 %

EYEN opened at $0.50 on Wednesday. Eyenovia, Inc. has a fifty-two week low of $0.37 and a fifty-two week high of $2.57. The firm has a market capitalization of $27.19 million, a P/E ratio of -0.67 and a beta of 1.74. The company’s 50-day moving average is $0.75 and its 200 day moving average is $0.79. The company has a debt-to-equity ratio of 3.72, a current ratio of 0.46 and a quick ratio of 0.27.

Eyenovia (NASDAQ:EYEN) last posted its earnings results on Monday, August 12th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.01). Eyenovia had a negative return on equity of 547.46% and a negative net margin of 116,506.25%. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $1.38 million. Research analysts expect that Eyenovia, Inc. will post -0.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Eyenovia news, CEO Michael M. Rowe acquired 50,000 shares of Eyenovia stock in a transaction on Monday, August 26th. The stock was purchased at an average price of $0.57 per share, for a total transaction of $28,500.00. Following the purchase, the chief executive officer now directly owns 82,927 shares of the company’s stock, valued at $47,268.39. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 7.10% of the stock is currently owned by corporate insiders.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.